Understanding the Market | HANSOH PHARMA opened nearly 2% higher, Goldman Sachs believes the company can promote or commercialize HS-10535 jointly in mainland China and Hong Kong-Macau or separately
I'm PortAI, I can summarize articles.
HANSOH PHARMA's stock price opened nearly 2% higher and, as of the time of writing, has risen 1.96% to HKD 18.7. Goldman Sachs released a report stating that HANSOH PHARMA has signed a global exclusive licensing agreement with Merck & Co. to obtain the sales rights for the oral GLP-1 drug HS-10535. Goldman Sachs believes that the company can promote this product in mainland China and Hong Kong and Macau, and is optimistic about the global potential of its innovative product line. HANSOH PHARMA's GLP-1 product portfolio is comprehensive, with another oral GLP-1 drug HS-10501 already in clinical trials
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments